Christopher Thomas Giordano net worth and biography

Christopher Giordano Biography and Net Worth

President and Chief Executive Officer of Tenax Therapeutics

Christopher Giordano is a clinical development executive with over 20 years of experience designing and executing product development strategies. He has served as Chief Executive Officer and a member of the Board of Directors of Tenax since July 2021, and as President since October 2021. Prior to Tenax, Mr. Giordano served as President of IQVIA Biotech and IQVIA MedTech, two full-service clinical research business units of IQVIA (formerly Quintiles) that provided comprehensive services to biotech, pharma, and device/diagnostic product development teams. At IQVIA, he led a team that significantly grew its clinical trial portfolio and produced double-digit annual sales growth during his leadership, while overseeing all consulting, regulatory, commercial, and clinical development services across various therapeutic areas including oncology, autoimmune, CNS, cardiovascular and renal diseases. In this role he oversaw all Phase 3 trials contributing to global approvals of a new oral anticoagulant, and executed over a dozen global cardiovascular outcomes trials in patients with heart, vascular, kidney and metabolic diseases, among other accomplishments. Before joining IQVIA, Mr. Giordano served in sales and operational management roles at PPD. Mr. Giordano received a BA in English from the University of San Diego, and a Masters in English from The University of North Carolina at Chapel Hill.

What is Christopher Thomas Giordano's net worth?: The estimated net worth of Christopher Thomas Giordano is at least $24.63 thousand as of November 19th, 2025. Mr. Giordano owns 2,067 shares of Tenax Therapeutics stock worth more than $24,628 as of June 17th. This net worth estimate does not reflect any other assets that Mr. Giordano may own. Learn More about Christopher Thomas Giordano's net worth.
How do I contact Christopher Thomas Giordano?: The corporate mailing address for Mr. Giordano and other Tenax Therapeutics executives is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. Tenax Therapeutics can also be reached via phone at 919-855-2100 and via email at [email protected]. Learn More on Christopher Thomas Giordano's contact information.
Has Christopher Thomas Giordano been buying or selling shares of Tenax Therapeutics?: Christopher Thomas Giordano has not been actively trading shares of Tenax Therapeutics within the last three months. Most recently, on Thursday, November 20th, Christopher Thomas Giordano bought 538 shares of Tenax Therapeutics stock. The stock was acquired at an average cost of $7.59 per share, with a total value of $4,083.42. Following the completion of the transaction, the chief executive officer now directly owns 2,605 shares of the company's stock, valued at $19,771.95. Learn More on Christopher Thomas Giordano's trading history.
Are insiders buying or selling shares of Tenax Therapeutics?: In the last twelve months, Tenax Therapeutics insiders bought shares 9 times. They purchased a total of 18,105 shares worth more than $149,053.47. The most recent insider tranaction occured on December, 8th when insider Stuart Rich bought 2,500 shares worth more than $25,250.00. Insiders at Tenax Therapeutics own 3.7% of the company. Learn More about insider trades at Tenax Therapeutics.
Information on this page was last updated on 12/8/2025.

Christopher Thomas Giordano Insider Trading History at Tenax Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/20/2025	Buy	538	$7.59	$4,083.42	2,605
11/19/2025	Buy	455	$7.51	$3,417.05	2,067
11/18/2025	Buy	1,612	$7.75	$12,493.00	1,612

Christopher Thomas Giordano Buying and Selling Activity at Tenax Therapeutics

Tenax Therapeutics Company Overview

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Today's Range

Now: $11.92

$11.26

$11.97

50 Day Range

MA: $12.60

$10.54

$15.11

2 Week Range

Now: $11.92

$5.34

$18.38

Volume

819,045 shs

Average Volume

493,865 shs

Market Capitalization

$316.17 million

P/E Ratio

N/A

Dividend Yield